Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They presently have a $9.00 price target on the stock.

A number of other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a report on Friday. JMP Securities initiated coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price target on the stock. Finally, Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $6.17.

Context Therapeutics Trading Up 0.2 %

Context Therapeutics stock opened at $0.77 on Friday. The business’s fifty day simple moving average is $0.85 and its two-hundred day simple moving average is $1.44. Context Therapeutics has a 12 month low of $0.64 and a 12 month high of $2.75. The company has a market capitalization of $57.88 million, a price-to-earnings ratio of -0.85 and a beta of 2.06.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. On average, equities research analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Trading of Context Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Shay Capital LLC purchased a new stake in Context Therapeutics during the fourth quarter valued at $52,000. MPM Bioimpact LLC purchased a new stake in Context Therapeutics during the fourth quarter valued at $15,441,000. Millennium Management LLC increased its position in Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after acquiring an additional 34,835 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Context Therapeutics during the fourth quarter valued at $31,000. Finally, Allostery Investments LP purchased a new stake in Context Therapeutics during the fourth quarter valued at $998,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.